健康伙伴应用程序作为提高房颤患者依从性和知识水平的新型工具:一项试点研究。
The Health Buddies App as a Novel Tool to Improve Adherence and Knowledge in Atrial Fibrillation Patients: A Pilot Study.
作者信息
Desteghe Lien, Kluts Kiki, Vijgen Johan, Koopman Pieter, Dilling-Boer Dagmara, Schurmans Joris, Dendale Paul, Heidbuchel Hein
机构信息
Faculty of Medicine and Life Sciences, Hasselt University, Hasselt, Belgium.
Heart Center Hasselt, Jessa Hospital, Hasselt, Belgium.
出版信息
JMIR Mhealth Uhealth. 2017 Jul 19;5(7):e98. doi: 10.2196/mhealth.7420.
BACKGROUND
Atrial fibrillation (AF) constitutes an important risk for stroke, especially in an ageing population. A new app (Health Buddies) was developed as a tool to improve adherence to non-vitamin K antagonist oral anticoagulants (NOACs) in an elderly AF population by providing a virtual contract with their grandchildren, spelling out daily challenges for both.
OBJECTIVE
The aim of this pilot study was to assess the feasibility and usability of the Health Buddies app in AF patients.
METHODS
Two workshops were conducted to steer app development and to test a first prototype. The feasibility of the finalized app was investigated by assessing the number of eligible AF patients (based on current prescription of NOACs, the presence of grandchildren between 5 and 15 years old, availability of a mobile phone, computer, or tablet), and the proportion of those who were willing to participate. Participants had to use the app for 3 months. The motivation of the patients to use the app was assessed based on the number of logins to the app. Their perception of its usefulness was examined by specific questionnaires. Additionally, the effects on knowledge level about AF and its treatment, and adherence to NOAC intake were investigated.
RESULTS
Out of 830 screened AF patients, 410 were taking NOACs and 114 were eligible for inclusion. However, only 3.7% (15/410) of the total NOAC population or 13.2% of the eligible patients (15/114) were willing to participate. The main reasons for not participating were no interest to participate in general or in the concept in particular (29/99, 29%), not feeling comfortable using technology (22/99, 22%), no interest by the grandchildren or their parents (20/99, 20%), or too busy a lifestyle (12/99, 12%). App use significantly decreased towards the end of the study period in both patients (P=.009) and grandchildren (P<.001). NOAC adherence showed a taking adherence and regimen adherence of 88.6% (SD 15.4) and 81.8% (SD 18.7), respectively. Knowledge level increased from 64.6% (SD 14.7) to 70.4% (SD 10.4) after 3 months (P=.09). The app scored positively on clarity, novelty, stimulation, and attractiveness as measured with the user experience questionnaire. Patients evaluated the educational aspect of this app as a capital gain.
CONCLUSIONS
Only a small proportion of the current AF population seems eligible for the innovative Health Buddies app in its current form. Although the app was positively rated by its users, a large subset of patients was not willing to participate in this study or to use the app. Efforts have to be made to expand the target group in the future.
背景
心房颤动(AF)是中风的重要危险因素,在老龄化人群中尤为如此。开发了一款新应用程序(健康伙伴),作为一种工具,通过与他们的孙辈签订虚拟契约,为老年房颤患者明确双方的日常挑战,从而提高他们对非维生素K拮抗剂口服抗凝剂(NOACs)的依从性。
目的
本试点研究的目的是评估健康伙伴应用程序在房颤患者中的可行性和可用性。
方法
举办了两次研讨会,以指导应用程序的开发并测试第一个原型。通过评估符合条件的房颤患者数量(基于当前NOACs处方、5至15岁孙辈是否存在、是否有手机、电脑或平板电脑)以及愿意参与的患者比例,来研究最终应用程序的可行性。参与者必须使用该应用程序3个月。根据应用程序登录次数评估患者使用该应用程序的动机。通过特定问卷检查他们对其有用性的看法。此外,还调查了对房颤及其治疗知识水平的影响以及对NOAC摄入的依从性。
结果
在830名接受筛查的房颤患者中,410人正在服用NOACs,114人符合纳入条件。然而,在整个服用NOACs的人群中,只有3.7%(15/410)或符合条件患者的13.2%(15/114)愿意参与。不参与的主要原因是总体上或特别是对该概念不感兴趣(29/99,29%)、使用技术感觉不自在(22/99,22%)、孙辈或其父母不感兴趣(20/99,20%)或生活方式太忙(12/99,12%)。在研究期结束时,患者(P = 0.009)和孙辈(P < 0.001)使用应用程序的情况均显著下降。NOAC依从性显示服用依从性和方案依从性分别为88.6%(标准差15.4)和81.8%(标准差18.7)。3个月后,知识水平从64.6%(标准差14.7)提高到70.4%(标准差10.4)(P = 0.09)。根据用户体验问卷测量,该应用程序在清晰度、新颖性、刺激性和吸引力方面得分呈阳性。患者将该应用程序的教育方面评价为一项收获。
结论
目前形式的创新型健康伙伴应用程序似乎仅适用于一小部分当前的房颤人群。尽管该应用程序得到了用户的积极评价,但很大一部分患者不愿意参与本研究或使用该应用程序。未来必须努力扩大目标群体。
相似文献
JMIR Mhealth Uhealth. 2017-7-19
引用本文的文献
Patient Prefer Adherence. 2025-4-7
Ther Clin Risk Manag. 2024-12-27
本文引用的文献
Eur Heart J Qual Care Clin Outcomes. 2016-10-1
Am J Cardiovasc Drugs. 2016-10
Telemed J E Health. 2017-2